前列腺導(dǎo)管內(nèi)癌48例治療經(jīng)驗及預(yù)后分析：一項單中心回顧性研究

打開文本圖片集

ABSTRACT：ObjectiveTo analyze and summarize the clinical characteristics and treatment methods of intraductal carcinoma of the prostate （IDC-P），so as to improve the diagnosis and treatment of this disease.MethodsThe clinical data of 48 IDC-P patients treated in Beijing Friendship Hospital during May 2017 and Mar.2024 were retrospectively analyzed.IDC-P was diagnosed by pathology in 27 cases by prostate puncture，in 2 cases by transurethral plasma resection of the prostate，and in 19 cases by radical prostatectomy.Of all patients，24 received radical prostatectomy，21 received direct endocrinotherapy，2 receivedprostate radioactive 125I implantation brachytherapy combine with androgen deprivation therapy，and 1 patient was observed and waiting.Kaplan-Meier method was used to analyze the main prognostic indicators.ResultsOne patient was lost to follow-up.Of the 47 patients followed up，24 underwent radical prostatectomy，of whom 22 underwent postoperative endocrinotherapy，and 10 had biochemical recurrence; 23 patients only received endocrinotherapy，and 14 of them had biochemical recurrence.Altogether 45 patients received endocrinotherapy，including 33 who received standardized treatment （21 hadbiochemical recurrence） and 12 who received novel treatment （3 had biochemical recurrence）.Survival analysis showed that radical prostatectomy had no significant impact on the biochemical recurrence after endocrinotherapy （P=0.250）.Novel endocrinotherapy could delay biochemical recurrence compared with standardized endocrinotherapy （P=0.003）.Conclusion Abiraterone or enzalutamide therapy can reduce the risk of biochemical recurrence，but further studies are needed to determine the optimal treatment for IDC-P patients.

摘要：

目的分析總結(jié)前列腺導(dǎo)管內(nèi)癌（IDC-P）的臨床特點和治療經(jīng)驗，提高臨床對IDC-P的診療水平。（剩余6004字）